Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:48:04 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:ALKS from 2023-04-27 to 2024-04-26 - 74 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 07:00U:ALKSNews ReleaseAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
2024-04-17 16:00U:ALKSNews ReleaseAlkermes to Report First Quarter Financial Results on May 1, 2024
2024-04-09 07:00U:ALKSNews ReleaseAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia
2024-04-08 07:00U:ALKSNews ReleaseAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI(TM) (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
2024-03-07 07:00U:ALKSNews ReleaseAlkermes Announces Appointment of Nancy S. Lurker to Board of Directors
2024-02-15 07:00U:ALKSNews ReleaseAlkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
2024-02-08 16:00U:ALKSNews ReleaseAlkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
2024-01-03 16:00U:ALKSNews ReleaseAlkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 07:00U:ALKSNews ReleaseAlkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI ‚ ® (olanzapine and samidorphan)
2023-12-27 11:47U:ALKSNews ReleaseEqual Opportunity and Respect: Diversity, Inclusion and Belonging at Alkermes
2023-12-20 12:20U:ALKSNews ReleaseCorporate Governance at Alkermes
2023-12-18 13:51U:ALKSNews ReleaseAlkermes' Commitment to Integrity and Compliance
2023-12-14 10:46U:ALKSNews ReleaseAlkermes' Culture of Employee Engagement and Wellness
2023-12-14 06:05U:ALKSNews ReleaseAlkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
2023-12-11 14:31U:ALKSNews ReleasePatient Advocacy and Community Engagement at Alkermes
2023-11-29 15:18U:ALKSNews ReleasePharmaceuticals in the Environment
2023-11-21 16:00U:ALKSNews ReleaseAlkermes to Participate in Two Upcoming Investor Conferences
2023-11-21 11:49U:ALKSNews ReleaseEnvironmental Protection & Sustainability at Alkermes
2023-11-20 13:52U:ALKSNews ReleaseAlkermes Celebrates #Movember for Men ¢ € ™s Health Awareness Month
2023-11-16 10:32U:ALKSNews ReleaseAlkermes' Waste Optimization Highlights
2023-11-15 07:00U:ALKSNews ReleaseAlkermes Completes Separation of Oncology Business
2023-11-14 13:48U:ALKSNews ReleaseOur Commitment to Caregivers
2023-11-13 12:48U:ALKSNews ReleaseProduct Stewardship and Environmental Impact at Alkermes
2023-11-10 15:01U:ALKSNews ReleaseCaring for Caregivers: Alkermes Celebrates National Caregivers Month
2023-11-08 11:32U:ALKSNews ReleaseEnvironmental Health and Safety at Alkermes
2023-11-07 16:00U:ALKSNews ReleaseAlkermes to Participate in the Jefferies London Healthcare Conference
2023-10-31 17:08U:ALKSNews ReleaseAlkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
2023-10-31 13:32U:ALKSNews ReleaseOperating and Growing Responsibly at Alkermes
2023-10-25 07:00U:ALKSNews ReleaseAlkermes plc Reports Third Quarter 2023 Financial Results
2023-10-23 14:04U:ALKSNews ReleaseAlkermes CEO Reflects on Living Company Purpose
2023-10-23 08:00U:ALKSNews ReleaseAlkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
2023-10-18 16:00U:ALKSNews ReleaseAlkermes to Report Third Quarter Financial Results on October 25, 2023
2023-10-16 12:33U:ALKSNews ReleaseCelebrating Global Diversity Awareness Month at Alkermes
2023-10-13 10:47U:ALKSNews ReleaseTake Time During Mental Health Awareness Week To Review These Resources
2023-10-11 12:01U:ALKSNews ReleaseAlkermes Proudly Announces Release of 2023 Corporate Responsibility Report
2023-10-10 17:00U:ALKSNews ReleaseMural Oncology to Host Investor Webcast on October 17
2023-10-10 07:00U:ALKSNews ReleaseAlkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
2023-09-21 13:01U:ALKSNews ReleaseAlkermes Pauses To Recognize National Ovarian Cancer Awareness Month
2023-09-19 11:09U:ALKSNews ReleaseAlkermes Pathways Research Awards Is Now Accepting Applications!
2023-09-18 13:16U:ALKSNews ReleaseAlkermes Commemorates World Suicide Prevention Day
2023-09-11 07:00U:ALKSNews ReleaseAlkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
2023-09-07 15:18U:ALKSNews ReleaseAlkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards(R) Program
2023-09-07 07:00U:ALKSNews ReleaseAlkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards ‚ ® Program
2023-09-05 16:00U:ALKSNews ReleaseAlkermes to Participate in Two Upcoming Investor Conferences
2023-08-31 07:00U:ALKSNews ReleaseAlkermes Announces Recipients of 2023 Alkermes Inspiration Grants ‚ ® Program
2023-08-30 07:00U:ALKSNews ReleaseAlkermes Announces Settlement With Teva Related to VIVITROL ‚ ® Patent Litigation
2023-08-28 10:37U:ALKSNews ReleaseAlkermes Honors Women's Equality Day
2023-08-21 10:48U:ALKSNews ReleaseBack to College? Talk to Your Student About Alcohol
2023-07-26 07:00U:ALKSNews ReleaseAlkermes plc Reports Second Quarter 2023 Financial Results
2023-07-24 13:49U:ALKSNews ReleaseAlkermes Awarded 2023 Platinum Bell Seal for Workplace Mental Health
2023-07-19 16:03U:ALKSNews ReleaseAlkermes to Report Second Quarter Financial Results on July 26, 2023
2023-07-19 11:31U:ALKSNews ReleaseAlkermes Celebrates Pride Month
2023-07-17 11:21U:ALKSNews ReleaseCelebrating 15 Years of Alkermes in Action
2023-06-29 10:50U:ALKSNews ReleaseAlkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders
2023-06-28 07:30U:ALKSNews ReleaseSarissa Capital Urges Alkermes Shareholders to Vote ¢ € œFOR ¢ €  Sarah Schlesinger and ¢ € œWITHHOLD ¢ €  Incumbent Director Richard Gaynor
2023-06-27 13:51U:ALKSNews ReleaseTips for Finding LGBTQ+ Competent Mental Health Care
2023-06-26 07:37U:ALKSNews ReleaseSarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
2023-06-26 07:00U:ALKSNews ReleaseRecently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders
2023-06-22 06:25U:ALKSNews ReleaseIndependent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders ¢ € ™ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
2023-06-21 08:00U:ALKSNews ReleaseIndependent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote "FOR" All Seven of the Company's Highly Qualified Director Nominees
2023-06-20 09:33U:ALKSNews ReleaseIndependent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
2023-06-20 07:00U:ALKSNews ReleaseIndependent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board
2023-06-15 07:58U:ALKSNews ReleaseSarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
2023-06-13 07:20U:ALKSNews ReleaseSarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
2023-06-13 07:00U:ALKSNews ReleaseAlkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors
2023-06-09 07:00U:ALKSNews ReleaseSarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
2023-06-08 07:00U:ALKSNews ReleaseAlkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation
2023-06-06 06:00U:ALKSNews ReleaseAlkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations
2023-06-05 07:00U:ALKSNews ReleaseSarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
2023-06-01 16:01U:ALKSNews ReleaseAlkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc
2023-05-31 16:00U:ALKSNews ReleaseAlkermes to Participate in Two Upcoming Investor Conferences
2023-05-16 07:00U:ALKSNews ReleaseAlkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences
2023-05-09 07:00U:ALKSNews ReleaseAlkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
2023-05-08 16:41U:ALKSNews ReleaseAlkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process